Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?

被引:7
作者
Adashek, Jacob J. [1 ]
Reed, Jarred P. [2 ]
Tandon, Ankita [1 ]
Freedland, Stephen J. [2 ,3 ,4 ]
Posadas, Edwin [2 ]
Bhowmick, Neil [2 ]
Chung, Leland W. [2 ]
Freeman, Michael [2 ]
Figlin, Robert A. [2 ]
Gong, Jun [2 ]
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Internal Med, Tampa, FL 33620 USA
[2] Samuel Oschin Comprehens Canc Inst, Los Angeles, CA USA
[3] Cedars Sinai Med Ctr, Dept Surg, Div Urol, Los Angeles, CA 90048 USA
[4] Durham VA Med Ctr, Sect Urol, Durham, NC USA
关键词
Androgen inhibition; Castration-sensitive; Docetaxel; Prostate cancer; CHEMOTHERAPY; THERAPY;
D O I
10.1016/j.clgc.2020.05.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The addition of docetaxel and abiraterone to androgen deprivation therapy (ADT) heralded a new era in the first-line treatment of metastatic castration-sensitive prostate cancer (mCSPC). Following the success of these combination regimens, 3 new trials presented data on using enzalutamide or apalutamide in men with mCSPC, which showed similar success. These seminal trials collectively established the addition of docetaxel, enzalutamide, apalutamide, or abiraterone to ADT as standards in the upfront treatment of mCSPC. Notably, a subset of patients in these more recent trials were treated with a combination of docetaxel, ADT, and androgen receptor signaling inhibitors or maintenance androgen receptor signaling inhibitors after docetaxel and ADT that provided an initial glimpse into the efficacy of these triplet or maintenance strategies. We discuss the implications of these recent findings and place them in context of the current mCSPC treatment landscape. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:425 / 428
页数:4
相关论文
共 13 条
[1]   ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer [J].
Armstrong, Andrew J. ;
Szmulewitz, Russell Z. ;
Petrylak, Daniel P. ;
Holzbeierlein, Jeffrey ;
Villers, Arnauld ;
Azad, Arun ;
Alcaraz, Antonio ;
Alekseev, Boris ;
Iguchi, Taro ;
Shore, Neal D. ;
Rosbrook, Brad ;
Sugg, Jennifer ;
Baron, Benoit ;
Chen, Lucy ;
Stenzl, Arnulf .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2974-+
[2]   Breast Cancer Screening and Diagnosis, Version 3.2018 [J].
Bevers, Therese B. ;
Helvie, Mark ;
Bonaccio, Ermelinda ;
Calhoun, Kristine E. ;
Daly, Mary B. ;
Farrar, William B. ;
Garber, Judy E. ;
Gray, Richard ;
Greenberg, Caprice C. ;
Greenup, Rachel ;
Hansen, Nora M. ;
Harris, Randall E. ;
Heerdt, Alexandra S. ;
Helsten, Teresa ;
Hodgkiss, Linda ;
Hoyt, Tamarya L. ;
Huff, John G. ;
Jacobs, Lisa ;
Lehman, Constance Dobbins ;
Monsees, Barbara ;
Niell, Bethany L. ;
Parker, Catherine C. ;
Pearlman, Mark ;
Philpotts, Liane ;
Shepardson, Laura B. ;
Smith, Mary Lou ;
Stein, Matthew ;
Tumyan, Lusine ;
Williams, Cheryl ;
Bergman, Mary Anne ;
Kumar, Rashmi .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (11) :1362-1389
[3]   Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer [J].
Chi, Kim N. ;
Agarwal, Neeraj ;
Bjartell, Anders ;
Chung, Byung Ha ;
Pereira de Santana Gomes, Andrea J. ;
Given, Robert ;
Juarez Soto, Alvaro ;
Merseburger, Axel S. ;
Ozguroglu, Mustafa ;
Uemura, Hirotsugu ;
Ye, Dingwei ;
Deprince, Kris ;
Naini, Vahid ;
Li, Jinhui ;
Cheng, Shinta ;
Yu, Margaret K. ;
Zhang, Ke ;
Larsen, Julie S. ;
McCarthy, Sharon ;
Chowdhury, Simon .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) :13-24
[4]   Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer [J].
Davis, Ian D. ;
Martin, Andrew J. ;
Stockler, Martin R. ;
Begbie, Stephen ;
Chi, Kim N. ;
Chowdhury, Simon ;
Coskinas, Xanthi ;
Frydenberg, Mark ;
Hague, Wendy E. ;
Horvath, Lisa G. ;
Joshua, Anthony M. ;
Lawrence, Nicola J. ;
Marx, Gavin ;
McCaffrey, John ;
McDermott, Ray ;
McJannett, Margaret ;
North, Scott A. ;
Parnis, Francis ;
Parulekar, Wendy ;
Pook, David W. ;
Reaume, M. Neil ;
Sandhu, Shahneen K. ;
Tan, Alvin ;
Tan, T. Hsiang ;
Thomson, Alastair ;
Tu, Emily ;
Vera-Badillo, Francisco ;
Williams, Scott G. ;
Yip, Sonia ;
Zhang, Alison Y. ;
Zielinski, Robert R. ;
Sweeney, Christopher J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) :121-131
[5]   Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer [J].
Fizazi, Karim ;
NamPhuong Tran ;
Fein, Luis ;
Matsubara, Nobuaki ;
Rodriguez-Antolin, Alfredo ;
Alekseev, Boris Y. ;
Ozguroglu, Mustafa ;
Ye, Dingwei ;
Feyerabend, Susan ;
Protheroe, Andrew ;
De Porre, Peter ;
Kheoh, Thian ;
Park, Youn C. ;
Todd, Mary B. ;
Chi, Kim N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :352-360
[6]   Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy [J].
James, N. D. ;
de Bono, J. S. ;
Spears, M. R. ;
Clarke, N. W. ;
Mason, M. D. ;
Dearnaley, D. P. ;
Ritchie, A. W. S. ;
Amos, C. L. ;
Gilson, C. ;
Jones, R. J. ;
Matheson, D. ;
Miliman, R. ;
Attard, G. ;
Chowdhury, S. ;
Cross, W. R. ;
Gillessen, S. ;
Parker, C. C. ;
Russell, J. M. ;
Berthold, D. R. ;
Brawley, C. ;
Adab, F. ;
Aung, S. ;
Birtle, A. J. ;
Bowen, J. ;
Brock, S. ;
Chakraborti, P. ;
Ferguson, C. ;
Gale, J. ;
Gray, E. ;
Hingorani, M. ;
Hoskin, P. J. ;
Lester, J. F. ;
Malik, Z. I. ;
McKinna, F. ;
McPhail, N. ;
Money-Kyrle, J. ;
O'Sullivan, J. ;
Parikh, O. ;
Protheroe, A. ;
Robinson, A. ;
Srihari, N. N. ;
Thomas, C. ;
Wagstaff, J. ;
Wylie, J. ;
Zarkar, A. ;
Parmar, M. K. B. ;
Sydes, M. R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :338-351
[7]   Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial [J].
James, Nicholas D. ;
Sydes, Matthew R. ;
Clarke, Noel W. ;
Mason, Malcolm D. ;
Dearnaley, David P. ;
Spears, Melissa R. ;
Ritchie, Alastair W. S. ;
Parker, Christopher C. ;
Russell, J. Martin ;
Attard, Gerhardt ;
de Bono, Johann ;
Cross, William ;
Jones, Rob J. ;
Thalmann, George ;
Amos, Claire ;
Matheson, David ;
Millman, Robin ;
Alzouebi, Mymoona ;
Beesley, Sharon ;
Birtle, Alison J. ;
Brock, Susannah ;
Cathomas, Richard ;
Chakraborti, Prabir ;
Chowdhury, Simon ;
Cook, Audrey ;
Elliott, Tony ;
Gale, Joanna ;
Gibbs, Stephanie ;
Graham, John D. ;
Hetherington, John ;
Hughes, Robert ;
Laing, Robert ;
McKinna, Fiona ;
McLaren, Duncan B. ;
O'Sullivan, Joe M. ;
Parikh, Omi ;
Peedell, Clive ;
Protheroe, Andrew ;
Robinson, Angus J. ;
Srihari, Narayanan ;
Srinivasan, Rajaguru ;
Staffurth, John ;
Sundar, Santhanam ;
Tolan, Shaun ;
Tsang, David ;
Wagstaff, John ;
Parmar, Mahesh K. B. .
LANCET, 2016, 387 (10024) :1163-1177
[8]   Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial [J].
Kyriakopoulos, Christos E. ;
Chen, Yu-Hui ;
Carducci, Michael A. ;
Liu, Glenn ;
Jarrard, David F. ;
Hahn, Noah M. ;
Shevrin, Daniel H. ;
Dreicer, Robert ;
Hussain, Maha ;
Eisenberger, Mario ;
Kohli, Manish ;
Plimack, Elizabeth R. ;
Vogelzang, Nicholas J. ;
Picus, Joel ;
Cooney, Matthew M. ;
Garcia, Jorge A. ;
DiPaola, Robert S. ;
Sweeney, Christopher J. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (11) :1080-+
[9]   Prostate Cancer, Version 2.2019 [J].
Mohler, James L. ;
Antonarakis, Emmanuel S. ;
Armstrong, Andrew J. ;
D'Amico, Anthony, V ;
Davis, Brian J. ;
Dorff, Tanya ;
Eastham, James A. ;
Enke, Charles A. ;
Farrington, Thomas A. ;
Higano, Celestia S. ;
Horwitz, Eric Mark ;
Hurwitz, Michael ;
Ippolito, Joseph E. ;
Kane, Christopher J. ;
Kuettel, Michael R. ;
Lang, Joshua M. ;
McKenney, Jesse ;
Netto, George ;
Penson, David F. ;
Plimack, Elizabeth R. ;
Pow-Sang, Julio M. ;
Pugh, Thomas J. ;
Richey, Sylvia ;
Roach, Mack, III ;
Rosenfeld, Stan ;
Schaeffer, Edward ;
Shabsigh, Ahmad ;
Small, Eric J. ;
Spratt, Daniel E. ;
Srinivas, Sandy ;
Tward, Jonathan ;
Shead, Dorothy A. ;
Freedman-Cass, Deborah A. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (05) :479-505
[10]   Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial [J].
Parker, Christopher C. ;
James, Nicholas D. ;
Brawley, Christopher D. ;
Clarke, Noel W. ;
Hoyle, Alex P. ;
Ali, Adnan ;
Ritchie, Alastair W. S. ;
Attard, Gerhardt ;
Chowdhury, Simon ;
Cross, William ;
Dearnaley, David P. ;
Gillessen, Silke ;
Gilson, Clare ;
Jones, Robert J. ;
Langley, Ruth E. ;
Malik, Zafar I. ;
Mason, Malcolm D. ;
Matheson, David ;
Millman, Robin ;
Russell, J. Martin ;
Thalmann, George N. ;
Amos, Claire L. ;
Alonzi, Roberto ;
Bahl, Amit ;
Birtle, Alison ;
Din, Omar ;
Douis, Hassan ;
Eswar, Chinnamani ;
Gale, Joanna ;
Gannon, Melissa R. ;
Jonnada, Sai ;
Khaksar, Sara ;
Lester, Jason F. ;
O'Sullivan, Joe M. ;
Parikh, Omi A. ;
Pedley, Ian D. ;
Pudney, Delia M. ;
Sheehan, Denise J. ;
Srihari, Narayanan Nair ;
Tran, Anna T. H. ;
Parmar, Mahesh K. B. ;
Sydes, Matthew R. .
LANCET, 2018, 392 (10162) :2353-2366